Greg Duncan, CEO, Virios Therapeutics
Armed with near-term catalyst, VIRI is poised for next growth stage
Development-stage biotechnology company Virios Therapeutics (NASDAQ:”VIRI”) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection. VIRI is anticipating top line results this September from its ongoing FM Phase 2b trial, featuring its lead combination antiviral development candidate, oral IMC-1. An earlier FM Phase 2a study demonstrated IMC-1’s effectiveness and tolerability better than placebo, which could serve as a distinguishing differentiating feature of IMC-1 versus other approved FM treatments.
FM is a medical condition experienced by approximately 2% of the population and is characterized by severe, widespread pain and fatigue, as well as symptoms pertaining to impaired mental health, such as anxiety and depression. Unfortunately, many patients suffering from FM are dissatisfied with available FM treatments. This dissatisfaction relates to both the limited FDA approved treatment options, all of which are focused solely on symptom management, and the burdensome side-effects often resulting in discontinuation of these approved therapies.
We sat down with Virios CEO Greg Duncan to find out more about the company’s research programs, target diseases and upcoming milestones.